

XBiotech Inc.  
Form 8-K  
January 05, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 5, 2018**

---

**XBIOTECH INC.**  
**(Exact name of Registrant as specified in its charter)**

---

**British  
Columbia,  
Canada**  
(State of  
Incorporation)

**001-37347**  
(Commission File Number)

**N/A**  
(I.R.S. Employer Identification No.)

**8201 E Riverside Dr. Bldg 4, Ste 100 78744**

**Austin, Texas**

(Zip Code)

(Address of principal executive offices)

**(512) 386-2900**

(Registrant's telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events.**

*Dismissal of Securities Class Action Civil Suit*

On January 5, 2018, XBiotech Inc. (the “Company”) announced that the United States District Court for the Western District of Texas Austin Division (the “Court”) has filed an order of dismissal granting in all respects a Notice of Voluntary Dismissal filed by the sole plaintiff in the putative class action complaint brought against certain officers of the Company on October 26, 2017 (Case 1:17-cv-01023-SS). The abovementioned lawsuit has therefore officially been dismissed without prejudice by the Court.

*This Form 8-K and the related press release contain forward-looking statements, including declarations regarding management's beliefs and expectations, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “would,” “could,” “expects,” “plans,” “contemplate,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “intend” or “continue” or the negative of such other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in “Risk Factors” in our SEC filings.*



**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 5, 2018 XBIOTECH INC.

By: /s/John Simard  
John Simard  
Chief Executive Officer and President